Monocyte and Lymphocyte Activation and Regulation in Multiple Sclerosis Patients. Therapy Effects
- 16 January 2019
- journal article
- research article
- Published by Springer Nature in Journal of Neuroimmune Pharmacology
- Vol. 14 (3) , 413-422
Abstract
Analysis of gut barrier status, monocyte and lymphocyte activation and T regulatory (Treg) cells at diagnosis before and after therapy, in patients with multiple sclerosis (MS). Analysis of differential effects of interferon beta (IFN-β), glatiramer acetate (GA) and natalizumab. Thirty-five patients with untreated MS were included. Gut barrier status (serum concentrations of intestinal fatty acid binding protein), monocyte (serum levels of soluble CD14, soluble CD163 and interleukin 6) and T lymphocyte activation (CD4 + DR+ and CD8 + DR+) and Treg (CD4 + CD25highFoxP3+) cells were analyzed. Patients with clinical isolated syndrome and relapsing-remitting forms were treated with IFN-β or GA, and immune characteristics were reevaluated following up after 6 months. A sample of 56 stable RR MS patients, in treatment with IFN-β, GA or natalizumab, and 50 healthy individuals were included as controls. Gut barrier status was similar in MS patients and healthy controls. Untreated patients with relapsing-remitting and primary progressive patterns of MS showed increased serum levels of soluble CD14. At baseline, significant increases in activated T lymphocytes and Treg were detected in patients. A significant decrease of CD4 + DR+, CD8 + DR+, and Treg percentages after 6 months of therapy was observed. In previously treated patients, IFN-β, GA, or natalizumab therapies were associated with a comparable cell proportion of activated lymphocytes and Treg. MS patients have a baseline state characterized by monocyte and lymphocyte activation, not related with gut barrier lesion. An increase in Treg number, correlated with activated T CD8+ lymphocytes, was detected. Treatment with IFN-β, GA or natalizumab was associated with a comparable decrease in activated lymphocytes and Treg.Keywords
Funding Information
- Neurolog?a, Fundaci?n para la Investigaci?n Biom?dica de C?diz
This publication has 35 references indexed in Scilit:
- Toll‐like receptors in the brain and their potential roles in neuropathologyImmunology & Cell Biology, 2007
- Proteolytic shedding of the macrophage scavenger receptor CD163 in multiple sclerosisJournal of Neuroimmunology, 2007
- Increased serum levels of soluble CD14 indicate stable multiple sclerosisJournal of Neuroimmunology, 2006
- Secondary progressive in contrast to relapsing‐remitting multiple sclerosis patients show a normal CD4+CD25+ regulatory T‐cell function and FOXP3 expressionJournal of Neuroscience Research, 2006
- Reduced suppressive effect of CD4+CD25high regulatory T cells on the T cell immune response against myelin oligodendrocyte glycoprotein in patients with multiple sclerosisEuropean Journal of Immunology, 2005
- Decreased FOXP3 levels in multiple sclerosis patientsJournal of Neuroscience Research, 2005
- CD14 Is an Acute-Phase ProteinThe Journal of Immunology, 2004
- The macrophage activity marker sCD14 is increased in patients with multiple sclerosis and upregulated by interferon beta-1bJournal of Neuroimmunology, 2002
- T-cell reactivity to multiple myelin antigens in multiple sclerosis patients and healthy controlsJournal of Neuroscience Research, 2001
- Interferon β in multiple sclerosis: is IL-12 suppression the key?Immunology Today, 2000